Genocea Biosciences Appoints John Sorvillo Vice President of Business Development.Biotech Business Development Executive Brings Solid Corporate Partnering Experience to Cutting Edge Vaccine Company CAMBRIDGE, Mass. -- Genocea Biosciences, a leading vaccine discovery and development company, today announced that John M. Sorvillo, Ph.D. has joined the company as Vice President of Business Development. "It is a great pleasure to welcome John to our team," said Staph staph n. Staphylococcus. staph adj. Leavenworth Bakali, Genocea's Chief Executive Officer. "John's extensive experience in business development and track record of success will be of great value to Genocea's partnering and business development activities." "Genocea has developed one of the most exciting approaches to vaccine discovery and is accelerating vaccine development in multiple multi-billion dollar market segments," said Dr. Sorvillo. "I am delighted to have the opportunity to be part of building a unique biotechnology company focused on novel prophylactic and therapeutic vaccines." Dr. Sorvillo was most recently Vice President of Business Development at Altus Pharmaceuticals [ALTU]. Before joining Altus, Dr. Sorvillo served as Chief Executive Officer of Bionaut Pharmaceuticals. Dr. Sorvillo was formerly Vice President of Business Development at ArQule [ARQL], where he was responsible for establishing many corporate technology and product collaborations with pharmaceutical companies. Prior to ArQule, Dr. Sorvillo held a variety of positions at OSI Pharmaceuticals [OSIP OSIP Open Source Integrated Portfolio OSIP Open Sip (session initiation protocol) OSIP Ohio Statewide Imagery Program OSIP Operational Safety Improvement Program OSIP Operational Suitability Improvement Program (aviation) ] (formerly Oncogene oncogene Gene that can cause cancer. It is a sequence of DNA that has been altered or mutated from its original form, the proto-oncogene (see mutation). Proto-oncogenes promote the specialization and division of normal cells. Science) leading up to his last position as Vice President and General Manager, Research Products Division. Dr. Sorvillo was a postdoctoral fellow at Memorial Sloan Kettering Cancer Center and received his Ph.D. in Immunology from the New York University New York University, mainly in New York City; coeducational; chartered 1831, opened 1832 as the Univ. of the City of New York, renamed 1896. It comprises 13 schools and colleges, maintaining 4 main centers (including the Medical Center) in the city, as well as the Medical Center, Sackler Institute of Biomedical Sciences. He holds a B.A. in Biology from the City University of New York The City University of New York (CUNY; acronym: IPA pronunciation: [kjuni]), is the public university system of New York City. , Hunter College. About Genocea Biosciences: Genocea Biosciences was founded in 2006 to commercialize key breakthroughs in vaccine discovery and development. The company's proprietary T cell-directed antigen discovery program represents a broad platform with the potential to generate significant novel vaccines for multiple pathogens with high unmet medical need. Genocea is currently developing vaccines for chlamydia trachomatis Chlamydia tra·cho·ma·tis n. A species of Chlamydia that causes trachoma, inclusion conjunctivitis, lymphogranuloma venereum, nonspecific urethritis, and proctitis in humans. (a sexually transmitted disease sexually transmitted disease (STD) or venereal disease, term for infections acquired mainly through sexual contact. Five diseases were traditionally known as venereal diseases: gonorrhea, syphilis, and the less common granuloma inguinale, with an estimated 90 million cases worldwide), streptococcus pneumoniae Streptococcus pneu·mo·ni·ae n. Pneumococcus. Streptococcus pneumoniae Microbiology A pathogenic streptococcus with 90 serotypes associated with pneumonia, bacteremia, meningitis Transmission Person to person Incidence (pneumonia is the leading killer of children under the age of five worldwide) and other undisclosed targets. In 2008, Genocea was selected as "Best Vaccine Startup" at the World Vaccine Congress and was selected one of the 15 most exciting biotech startup companies by FierceBiotech. Genocea is backed by leading investors including Lux Capital Management, Polaris Venture Partners, SR One, Auriga Partners, Cycad cycad (sī`kăd), any plant of the order Cycadales, tropical and subtropical palmlike evergreens. The cycads, ginkgoes, and conifers comprise the three major orders of gymnosperms, or cone-bearing plants (see cone and plant). Group, Morningside Ventures, and Alexandria Real Estate Equities. Visit www.genocea.com for more information. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion